Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases

Author(s): Yongqiang Zhu, Qingzhi Gao.

Journal Name: Recent Patents on Biomedical Engineering (Discontinued)

Volume 2 , Issue 3 , 2009

Abstract:

The ubiquitin-proteasome pathway (UPP) is the major proteolytic process that degrades the intracellular proteins in a regulated way. Deregulation of the UPP has been implicated in the pathogenesis of a number of major human diseases including cancer, viral infections, neurodegenerative disorder, cardiovascular disorder, diabetes, etc. The successful market of a patented drug bortezomib validated the proteasome as an effective target in the treatment of cancers. It also demonstrated the potential of proteasome as a biological target in the design of the drugs against other major human diseases stated above. This review presents the development status of the proteasome inhibitors and their application in many diseases and recent patent coverage.

Keywords: Proteasomes inhibitor, ubiquitin proteasome pathway (UPP), anticancer drug, antivirus, cardiovascular disease, neurodegenerative disease, diabetes

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 3
Year: 2009
Page: [180 - 192]
Pages: 13
DOI: 10.2174/1874764710902030180
Price: $58

Article Metrics

PDF: 8